Research location
Pretoria
Gauteng, South Africa
Advertisement
Research activity in Pretoria
Gauteng, South AfricaCureCurrent currently publishes aggregate city-level research activity for this location: 233 trials and 334 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Pretoria
233 linked trials · page 2 of 5A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)NCT04777409 · 2021-05-18 · 1 site observation
COMPLETED
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02)NCT04700072 · 2021-05-03 · 1 site observation
COMPLETED
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)NCT04700124 · 2021-04-21 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)NCT04736706 · 2021-04-14 · 3 site observations
ACTIVE_NOT_RECRUITING
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)NCT04738487 · 2021-04-07 · 1 site observation
TERMINATED
Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022)NCT04644029 · 2021-02-24 · 1 site observation
TERMINATED
Darolutamide in Addition to ADT Versus ADT in Metastatic Hormone-sensitive Prostate CancerNCT04736199 · 2021-02-23 · 1 site observation
COMPLETED
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)NCT04624204 · 2020-12-08 · 1 site observation
ACTIVE_NOT_RECRUITING
A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African AdultsNCT04533399 · 2020-08-17 · 2 site observations
COMPLETED
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)NCT04305054 · 2020-07-01 · 2 site observations
COMPLETED
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)NCT04152863 · 2020-06-05 · 3 site observations
TERMINATED
Long-term Safety and Efficacy of GSK3196165 (Otilimab) in the Treatment of Rheumatoid Arthritis (RA)NCT04333147 · 2020-05-12 · 1 site observation
TERMINATED
A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid ArthritisNCT04230213 · 2020-01-13 · 2 site observations
COMPLETED
Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) InhibitorsNCT04134728 · 2019-10-31 · 1 site observation
COMPLETED
A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical PracticeNCT04042441 · 2019-07-29 · 1 site observation
COMPLETED
A Heart Disease Study of Semaglutide in Patients With Type 2 DiabetesNCT03914326 · 2019-06-17 · 2 site observations
COMPLETED
A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964 · 2019-04-25 · 1 site observation
COMPLETED
Long-term Safety and Efficacy Extension Trial of Bimatoprost SRNCT03891446 · 2019-03-27 · 1 site observation
COMPLETED
Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular HypertensionNCT03850782 · 2019-02-28 · 1 site observation
COMPLETED
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)NCT03740165 · 2018-12-18 · 4 site observations
COMPLETED
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)NCT03675737 · 2018-11-08 · 1 site observation
COMPLETED
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityNCT03574597 · 2018-10-24 · 3 site observations
COMPLETED
A Research Study to Compare the Effect of Insulin Degludec and Insulin Glargine on Blood Sugar Levels in People With Type 2 Diabetes - the SWITCH PRO StudyNCT03687827 · 2018-10-02 · 1 site observation
COMPLETED
A Research Study to Compare Semaglutide to Insulin Aspart, When Taken Together With Metformin and Insulin Glargine, in People With Type 2 DiabetesNCT03689374 · 2018-10-01 · 2 site observations
COMPLETED
A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)NCT03516981 · 2018-10-01 · 1 site observation
COMPLETED
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)NCT03553836 · 2018-09-12 · 2 site observations
ACTIVE_NOT_RECRUITING
PeriOperative ISchemic Evaluation-3 TrialNCT03505723 · 2018-06-27 · 1 site observation
COMPLETED
Patient-reported Outcomes in Vericiguat-treated Patients With HFpEFNCT03547583 · 2018-06-15 · 1 site observation
COMPLETED
Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or ObesityNCT03552757 · 2018-06-04 · 2 site observations
COMPLETED
Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or ObesityNCT03548987 · 2018-06-04 · 2 site observations
COMPLETED
Study of Hip and Knee Arthroplasty in South AfricaNCT03540667 · 2018-05-07 · 1 site observation
COMPLETED
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)NCT03425643 · 2018-04-24 · 1 site observation
ACTIVE_NOT_RECRUITING
Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02NCT03426345 · 2018-02-16 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04NCT03383146 · 2018-02-01 · 1 site observation
TERMINATED
A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03NCT03420781 · 2018-01-24 · 2 site observations
TERMINATED
Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)NCT03302234 · 2017-12-14 · 1 site observation
COMPLETED
Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With AsthmaNCT03248128 · 2017-10-20 · 2 site observations
COMPLETED
Phase IIb Study of Evobrutinib in Subjects With Rheumatoid ArthritisNCT03233230 · 2017-09-18 · 2 site observations
COMPLETED
Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT)NCT03061214 · 2017-08-28 · 1 site observation
COMPLETED
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 2 site observations
ACTIVE_NOT_RECRUITING
A 24-week Study to Compare Umeclidinium/Vilanterol (UMEC/VI), UMEC and Salmeterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT03034915 · 2017-06-16 · 2 site observations
COMPLETED
Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed DyslipidemiaNCT02833844 · 2017-05-22 · 1 site observation
COMPLETED
Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe PreeclampsiaNCT03008616 · 2017-04-12 · 1 site observation
TERMINATED
Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)NCT03071692 · 2017-03-23 · 4 site observations
TERMINATED
A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)NCT03033511 · 2017-02-07 · 2 site observations
TERMINATED
A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 DiabetesNCT02692716 · 2017-01-17 · 1 site observation
COMPLETED
Nutrition Education Intervention for Adults With Type 2 DiabetesNCT03334773 · 2017-01-16 · 1 site observation
COMPLETED
A Study of Abemaciclib (LY2835219) in Participants With Breast CancerNCT02763566 · 2016-12-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Transcutaneous Pulsed Radiofrequency for the Treatment of Diabetic Peripheral Neuropathy PainNCT07725419 · 2016-12-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.